UK-315716/UK-240455. Pfizer.

A M, Capelli; F, Micheli

Found an issue? Give us feedback

https://pubmed.ncbi....arrow_drop_down

https://pubmed.ncbi.nlm.nih.go...

Article . 2002

Data sources: Europe PubMed Central

UK-315716/UK-240455. Pfizer.

descriptionPublicationkeyboard_double_arrow_right Article 29 Aug 2002 English Journal:Current opinion in investigational drugs (London, England : 2000), volume 2 (issn: 1472-4472,

Copyright policy )

Authors: A M, Capelli; F, Micheli;

pmid: 11892937

UK-315716/UK-240455. Pfizer.

- Summary
- Subjects
- Metrics

Abstract

Pfizer is developing the atropoisomeric quinoxalinediones, UK-315716 and UK-240255, from a series of NMDA/glycine antagonists for the potential treatment of stroke. Both are compounds are undergoing clinical trials. UK-315716 has improved aqueous solubility and in vivo efficacy over UK-240455, and a lower projected clinical dose of 200 mg compared to 500 mg with UK-240455.

Related Organizations

GlaxoSmithKline (Italy)
Italy

Keywords

Structure-Activity Relationship, Neuroprotective Agents, Receptors, Glycine, Clinical Trials, Phase I as Topic, Quinoxalines, Animals, Humans, Receptors, N-Methyl-D-Aspartate

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average